Literature DB >> 21636340

[Primary hyperoxaluria].

Pierre Cochat1, Sonia Fargue, Justine Bacchetta, Aurélia Bertholet-Thomas, Jean-François Sabot, Jérôme Harambat.   

Abstract

Primary hyperoxalurias are rare recessive inherited inborn errors of glyoxylate metabolism. They are responsible for progressive renal involvement, which further lead to systemic oxalate deposition, which can even occur in infants. Primary hyperoxaluria type 1 is the most common form in Europe and is due to alanine-glyoxylate aminostransferase deficiency, a hepatic peroxisomal pyridoxin-dependent enzyme. Therefore primary hyperoxaluria type 1 is responsible for hyperoxaluria leading to aggressive stone formation and nephrocalcinosis. As glomerular filtration rate decreases, systemic oxalate storage occurs throughout all the body, and mainly in the skeleton. The diagnosis is first based on urine oxalate measurement, then on genotyping, which may also allow prenatal diagnosis to be proposed. Conservative measures - including hydration, crystallization inhibitors and pyridoxine - are safe and may allow long lasting renal survival, provided it is given as soon as the diagnosis has been even suspected. No dialysis procedure can remove enough oxalate to compensate oxalate overproduction from the sick liver, therefore a combined liver and kidney transplantation should be planned before advanced renal disease has occurred, in order to limit/avoid systemic oxalate deposition. In the future, primary hyperoxaluria type 1 may benefit from hepatocyte transplantation, chaperone molecules, etc.
Copyright © 2011 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636340     DOI: 10.1016/j.nephro.2011.03.004

Source DB:  PubMed          Journal:  Nephrol Ther        ISSN: 1769-7255            Impact factor:   0.722


  3 in total

1.  Two novel AGXT mutations identified in primary hyperoxaluria type-1 and distinct morphological and structural difference in kidney stones.

Authors:  Cui Wang; Jingru Lu; Yanhua Lang; Ting Liu; Xiaoling Wang; Xiangzhong Zhao; Leping Shao
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

2.  Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.

Authors:  Chaitali Dutta; Nicole Avitahl-Curtis; Natalie Pursell; Marita Larsson Cohen; Benjamin Holmes; Rohan Diwanji; Wei Zhou; Luciano Apponi; Martin Koser; Bo Ying; Dongyu Chen; Xue Shui; Utsav Saxena; Wendy A Cyr; Anee Shah; Naim Nazef; Weimin Wang; Marc Abrams; Henryk Dudek; Eduardo Salido; Bob D Brown; Chengjung Lai
Journal:  Mol Ther       Date:  2016-01-13       Impact factor: 11.454

3.  A Network Pharmacology Study on the Mechanisms of the Herbal Extract, Christina Loosestrife, for the Treatment of Nephrolithiasis.

Authors:  Kun Yu; Ping Zhang; Zhen-Guo Xie
Journal:  Med Sci Monit       Date:  2020-04-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.